文献速递肺血管病与心包/心肌炎冠心病血脂与心血管预防

症状性心血管疾病患者的心血管危险因素与主要不良肢体事件风险

Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease.
PubMed 文献 · Heart · 2020-03-13

本研究基于Utrecht心血管队列-动脉疾病二级表现研究(1996-2017),纳入8139例症状性血管疾病患者,中位随访7.8年,观察577例MALE和1933例MALE/MACE。发现非HDL-c、收缩压和吸烟对MALE风险的影响因血管疾病部位而异,在PAD与非PAD患者中表现不同。

要点

  • 在CAD/CVD/AAA患者中,非HDL-c每升高1 mmol/L,MALE风险增加(HR 1.14)。
  • 收缩压每升高10 mm Hg,PAD患者MALE风险HR 1.06,CAD/CVD/AAA患者HR 1.15。
  • 吸烟者MALE风险显著升高,CAD/CVD/AAA患者HR达7.08。

核心结论

  • 症状性血管疾病患者的MALE和MALE/MACE风险因血管疾病部位不同而异,并与非HDL-c、收缩压和吸烟相关。
  • 研究结果强调MALE作为结局的重要性,并突显血管疾病患者危险因素管理的必要性。

研究设计与样本

  • 来自Utrecht心血管队列-动脉疾病二级表现研究(1996-2017)的症状性血管疾病患者。
  • 共纳入8139例患者,中位随访7.8年(IQR 4.0-11.8)。
  • 采用Cox比例风险模型,按外周动脉疾病(PAD)是否存在进行分层分析。
  • MALE定义为下肢主要截肢、外周血运重建或溶栓。

主要发现

  • 共观察577例MALE(8.7/1000人年)和1933例MALE/MACE(29.1/1000人年)。
  • PAD患者中非HDL-c与MALE无关联;CAD、CVD或AAA患者中,非HDL-c每升高1 mmol/L,MALE风险HR 1.14(95% CI 1.01-1.29)。
  • 收缩压每升高10 mm Hg,PAD患者MALE风险HR 1.06(95% CI 1.01-1.12),CVD/CAD/AAA患者HR 1.15(95% CI 1.08-1.22)。
  • 吸烟者MALE风险:PAD患者HR 1.45(95% CI 0.97-2.14),CAD/CVD/AAA患者HR 7.08(95% CI 3.99-12.57)。

临床怎么用

  • 在症状性血管疾病患者中应重视非HDL-c、收缩压和吸烟等危险因素的管理,以降低MALE风险。
  • 不同血管疾病部位患者的危险因素对MALE的影响存在差异,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To determine the relationship between non-high-density lipoprotein cholesterol (non-HDL-c), systolic blood pressure (SBP) and smoking and the risk of major adverse limb events (MALE) and the combination with major adverse cardiovascular events (MALE/MACE) in patients with symptomatic vascular disease. METHODS: Patients with symptomatic vascular disease from the Utrecht Cardiovascular Cohort - Secondary Manifestations of ARTerial disease (1996-2017) study were included. The effects of non-HDL-c, SBP and smoking on the risk of MALE were analysed with Cox proportional hazard models stratified for presence of peripheral artery disease (PAD). MALE was defined as major amputation, peripheral revascularisation or thrombolysis in the lower limb. RESULTS: In 8139 patients (median follow-up 7.8 years, IQR 4.0-11.8), 577 MALE (8.7 per 1000 person-years) and 1933 MALE/MACE were observed (29.1 per 1000 person-years). In patients with PAD there was no relation between non-HDL-c and MALE, and in patients with coronary artery disease (CAD), cerebrovascular disease (CVD) or abdominal aortic aneurysm (AAA) the risk of MALE was higher per 1 mmol/L non-HDL-c (HR 1.14, 95% CI 1.01 to 1.29). Per 10 mm Hg SBP, the risk of MALE was higher in patients with PAD (HR 1.06, 95% CI 1.01 to 1.12) and in patients with CVD/CAD/AAA (HR 1.15, 95% CI 1.08 to 1.22). The risk of MALE was higher in smokers with PAD (HR 1.45, 95% CI 0.97 to 2.14) and CAD/CVD/AAA (HR 7.08, 95% CI 3.99 to 12.57). CONCLUSIONS: The risk of MALE and MALE/MACE in patients with symptomatic vascular disease differs according to vascular disease location and is associated with non-HDL-c, SBP and smoking. These findings confirm the importance of MALE as an outcome and underline the importance of risk factor management in patients with vascular disease.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Hageman SHJ, de Borst GJ, Dorresteijn JAN, et al. Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart. 2020. PMID: 32170038. doi:10.1136/heartjnl-2019-316088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。